Genexine Inc
095700
Company Profile
Business description
Genexine Inc is a clinical-stage biotechnology company. It is focused on the development and commercialization of immunotherapeutics and next-generation long-acting biologics. Its primary technologies are Therapeutic DNA vaccine technology and Hyfc platform. The company's product pipeline includes products such as GX-H9, GX-E2, GX-G3, GX-G6, and Papitrol-188 among others.
Contact
700 Daewangpangyo-ro, Gyeonggi-do
Korea Bio Park Building B, Bundang-gu
Seongnam-si13488
KORT: +82 316283200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
80
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,677.50 | 170.10 | -2.17% |
| CAC 40 | 7,017.50 | 257.45 | -3.54% |
| DAX 40 | 20,010.11 | 631.61 | -3.06% |
| Dow JONES (US) | 37,822.40 | 2,723.53 | -6.72% |
| FTSE 100 | 7,802.51 | 252.47 | -3.13% |
| HKSE | 20,140.78 | 2,709.03 | -11.86% |
| NASDAQ | 15,556.05 | 994.56 | -6.01% |
| Nikkei 225 | 32,721.87 | 1,058.71 | -3.13% |
| NZX 50 Index | 11,917.55 | 307.73 | -2.52% |
| S&P 500 | 5,041.94 | 32.14 | -0.63% |
| S&P/ASX 200 | 7,482.20 | 185.60 | -2.42% |
| SSE Composite Index | 3,124.77 | 28.20 | 0.91% |